NeoPharm Co

NeoPharm Co Intangible Assets

The Intangible Assets of NeoPharm Co (092730.KQ) as of Nov 5, 2026 is 1.95 B KRW. In the previous year, Intangible Assets was 2.24 B KRW — a change of -12.78% (lower).

Intangible Assets

1.95 BKRW

YoY

-12.78%

Last updated:

Intangible Assets of NeoPharm Co is 2024 1.95 B KRW. Intangible Assets of NeoPharm Co was 2023 2.24 B KRW. It decreases by -12.78% lower compared to the previous year.

The NeoPharm Co Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
1.20 B KRW
Jan 1, 2018
1.17 B KRW
Jan 1, 2019
2.38 B KRW
Jan 1, 2020
2.38 B KRW
Jan 1, 2021
2.06 B KRW
Jan 1, 2022
1.79 B KRW
Jan 1, 2023
2.24 B KRW
Jan 1, 2024
1.95 B KRW
The NeoPharm Co Intangible Assets history
YEARIntangible AssetsYoY
1.95 BKRW-12.78%
2.24 BKRW+25.21%
1.79 BKRW-13.07%
2.06 BKRW-13.65%
2.38 BKRW-0.17%
2.38 BKRW+103.59%
1.17 BKRW-2.66%
1.20 BKRW-2.12%
1.23 BKRW+11.93%
1.10 BKRW-12.51%
1.26 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NeoPharm Co Stock analysis

What does NeoPharm Co do? NeoPharm Co., Ltd. generates revenue through the development, manufacture, and sale of cosmetics, medical, and health products under its own brand names. The company sells ATOPALM products, which include daily care, intensive care, special care, and baby care items, as well as Derma:B products such as foam cleansers, oil cleansers, toners, emulsions, creams, facial masks, BB creams, sun protectors, white watering serums, and anti-aging eye creams. ZEROID products, featuring creams and lotions for skin barrier recovery and hypoallergenic foaming cleansers for atopic and sensitive skin, also contribute to sales. Additionally, NeoPharm provides original equipment manufacturing (OEM) services for skin drugs, supplying these to other companies. The primary buyers of NeoPharm's products are consumers seeking skincare solutions for daily use, sensitive skin conditions, and medical-grade treatments. ATOPALM targets general skincare and baby care markets, while Derma:B appeals to users looking for comprehensive skincare routines including anti-aging and sun protection. ZEROID focuses on individuals with atopic or sensitive skin requiring gentle, hypoallergenic products. OEM services are purchased by other pharmaceutical companies needing skin drug manufacturing capabilities. NeoPharm's product portfolio is structured around four key brands: ATOPALM, Derma:B, ZEROID, and OEM services. ATOPALM and Derma:B cater to broad consumer segments in the cosmetics and skincare industry, with Derma:B offering a wide range of products for various skin concerns. ZEROID serves a specialized segment for sensitive skin care, and OEM services target business-to-business clients in the pharmaceutical sector. The company's revenue streams are thus diversified across consumer-facing brands and B2B manufacturing contracts. NeoPharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NeoPharm Co stock

Intangible Assets of NeoPharm Co is 1.95 B KRW in 2024.

Intangible Assets of NeoPharm Co changed from 2.24 B KRW to 1.95 B KRW, representing a -12.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets NeoPharm Co since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's NeoPharm Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — NeoPharm Co

All Key Metrics — NeoPharm Co